bioRxivBiochemistry
Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLRthat is shed by Furin
D. Susan-Resiga, E. Girard, R. Essalmani, A. Roubtsova, J. Marcinkiewicz, R. M. Derbali, A. Evagelidis, J. H. Byun, P. F. Lebeau, R. C. Austin, N. G. Seidah
Abstract
The hepatic carbohydrate-recognizing asialoglycoprotein receptor (ASGR1) mediates the endocytosis/lysosomal degradation of desialylated glycoproteins following binding to terminal galactose/N-acetylgalactosamine. Human heterozygote-carriers of ASGR1-deletions exhibited [~]34% lower risk of coronary artery disease and [~]10-14% non-HDL-cholesterol reduction. Since PCSK9 is a major degrader of LDLR, the regulation of LDLR and/or PCSK9 by ASGR1 was studied. Thus, we investigated the role of endogenous/overexpressed ASGR1 on LDLR degradation and functionality by Western-blot and immunofluorescence in HepG2 naive and HepG2-PCSK9-knockout cells. ASGR1, like PCSK9, targets LDLR and both interact with/enhance the degradation of the receptor independently. Such lack of cooperativity between PCSK9 and ASGR1 on LDLR expression was confirmed in livers of wild-type (WT) versus Pcsk9-/- mice. ASGR1-knockdown in HepG2 naive cells significantly increased total ([~]1.2-fold) and cell-surface ([~]4-fold) LDLR protein. In HepG2-PCSK9-knockout cells ASGR1-silencing led to [~]2-fold higher levels of LDLR protein and DiI-LDL uptake, associated with [~]9-fold increased cell-surface LDLR. Overexpression of WT-ASGR1/2 reduced primarily the immature non-O-glycosylated LDLR ([~]110 kDa), whereas the triple Gln240/Trp244/Glu253 Ala-mutant (loss of carbohydrate-binding) reduced the mature form of the LDLR ([~]150 kDa), suggesting that ASGR1 binds the LDLR in sugar-dependent and -independent fashion. Furin sheds ASGR1 at RKMK103{downarrow} into a secreted form, likely resulting in a loss-of-function on LDLR. LDLR is the first example of a liver-receptor ligand of ASGR1. Additionally, we demonstrate that lack of ASGR1 enhances LDLR levels and DiI-LDL incorporation, independently of PCSK9. Overall, silencing of ASGR1 and PCSK9 may lead to higher LDL-uptake by hepatocytes, thereby providing a novel approach to further reduce LDL-cholesterol.
- organism: human
- assay: proteomics
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cell-associated, Heparin-like Molecules Modulate the Ability of LDL to Regulate PCSK9 Uptake
A. M. Galvan, J. S. Chorba·bioRxiv·May 23, 2018
- Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: functional regulation of LDLR levels
Carole Fruchart‐Gaillard, Ali Ben Djoudi Ouadda, … Nabil Georges Seidah·Molecular MetabolismPeer-reviewed·Dec 22, 2022
- Targeting Liver Epsins Ameliorates Dyslipidemia in Atherosclerosis through Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9-Mediated Low-density Lipoprotein Receptor Degradation
Bo Zhu, Krishan Gupta, … Hong Chen·bioRxiv·Aug 26, 2024
- Loss of asgr1a leads to the secretion of excess dietary cholesterol in zebrafish
Joshua T. Derrick, Tabea O. C. Moll, … Steven Arthur Farber·Journal of Biological ChemistryPeer-reviewed·Jun 9, 2026
- Non-Canonical Binding of a Small Molecule to Sortilin Alters Cellular Trafficking of ApoB and PCSK9 in Liver Derived Cells
R. P. Sparks, A. S. Arango, … R. A. Fratti·bioRxiv·Oct 7, 2019
- CSDE1 is a Post-Transcriptional Regulator of the LDL Receptor
Geoffrey A. Smith, Arun Padmanabhan, … John S. Chorba·Science Translational MedicinePeer-reviewed·Sep 14, 2022